Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alexandre Durand-Salmon"'
Autor:
Mously Dior Diaw, Stéphane Papelier, Alexandre Durand-Salmon, Jacques Felblinger, Julien Oster
Publikováno v:
IEEE Transactions on Biomedical Engineering. 70:1504-1515
Rate-corrected QT interval (QTc) prolongation has been suggested as a biomarker for the risk of drug-induced torsades de pointes, and is therefore monitored during clinical trials for the assessment of drug safety. Manual QT measurements by expert EC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1b1114a6cd0184f64247e62ab5d272
https://doi.org/10.1109/tbme.2022.3221339
https://doi.org/10.1109/tbme.2022.3221339
Autor:
'Mously Dior Diaw, Stéphane Papelier, Alexandre Durand-Salmon, Jacques Felblinger, Julien Oster\\'
Publikováno v:
Computing in Cardiology Conference (CinC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048400183ddb4ea29b3ac55041a220ee
https://doi.org/10.22489/cinc.2022.040
https://doi.org/10.22489/cinc.2022.040
Autor:
Antoine Leenhardt, Edi Prifti, Jean-Daniel Zucker, Dan M. Roden, Christian Funck-Brentano, Alfredo Aram Pulini, Giovanni Davogustto, Joe-Elie Salem, Fabrice Extramiana, Quinn S. Wells, Ahmad Fall, Alexandre Durand-Salmon, Yasmin Khan, Isabelle Denjoy
Congenital or drug-induced long-QT syndromes can cause Torsade-de-Pointes (TdP), a life-threatening ventricular arrhythmia. The current strategy to identify individuals at high risk of TdP consists on measuring the QT duration on the electrocardiogra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32f3e7746c15fcc2bec6fbe242a5424c
https://doi.org/10.21203/rs.3.rs-256040/v1
https://doi.org/10.21203/rs.3.rs-256040/v1
Publikováno v:
Proceedings of the 3rd Workshop on Machine Reading for Question Answering.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4441aa25a40fb3003deef94ffc794efe
https://doi.org/10.18653/v1/2021.mrqa-1.5
https://doi.org/10.18653/v1/2021.mrqa-1.5
Publikováno v:
Proceedings of the Second Workshop on Natural Language Processing for Medical Conversations
NLPMC 2021-Second Workshop on Natural Language Processing for Medical Conversations
NLPMC 2021-Second Workshop on Natural Language Processing for Medical Conversations, Jun 2021, Mexico, Mexico. pp.21-29
NLPMC 2021-Second Workshop on Natural Language Processing for Medical Conversations
NLPMC 2021-Second Workshop on Natural Language Processing for Medical Conversations, Jun 2021, Mexico, Mexico. pp.21-29
International audience; We focus on dialog models in the context of clinical studies where the goal is to help gather, in addition to the closed set of information collected based on a questionnaire, serendipitous information that is medically releva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e08ea44ee4bb26ae8f774e904a7be1e
https://doi.org/10.18653/v1/2021.nlpmc-1.3
https://doi.org/10.18653/v1/2021.nlpmc-1.3
Publikováno v:
Proceedings of the 28th Conference on Computational Linguistics
Proceedings of the 28th Conference on Computational Linguistics, Dec 2020, Barcelona, Spain
COLING
Proceedings of the 28th Conference on Computational Linguistics, Dec 2020, Barcelona, Spain
COLING
International audience; A key bottleneck for developing dialog models is the lack of adequate training data. Due to privacy issues, dialog data is even scarcer in the health domain. We propose a novel method for creating dialog corpora which we apply
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1abcfd5b643439feb1a0ef39511d3f29
https://hal.science/hal-03020294/document
https://hal.science/hal-03020294/document
Autor:
Alexandre Durand-Salmon, Mathieu Felices, Matthias Ocker, Gerard Nitenberg, Antoine Hollebecque, Charles Ferté, Jean-Charles Soria
Publikováno v:
Cancer Research. 74:900-900
Background: Recent studies suggest that tumor shrinkage as measured by RECIST 1.1 criteria may not be adequate to assess early signs of anti-tumor activity in phase I trials. The value of Tumor Growth Rate (TGR) evaluation in this context has been su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::492d54c9a195b0df8ad593c332c37781
https://doi.org/10.1158/1538-7445.am2014-900
https://doi.org/10.1158/1538-7445.am2014-900